Low-level red-light therapy for dry age-related macular degeneration
Part of Eyes & vision clinical trials.
This trial tests if repeated low-level red-light therapy can help people with dry age-related macular degeneration (AMD), a condition that causes gradual vision loss. The therapy uses red light to potentially slow or improve vision problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older.
- You have dry AMD, not the wet type, at an early, intermediate, or advanced stage.
- Your vision in the study eye is between 20/32 and 20/100 on an eye chart.
- You have not had any invasive eye surgery in the last 3 months.
- You do not have other eye diseases that could affect vision, like glaucoma or diabetic eye problems.
- You do not have a history of epilepsy or cognitive problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special laser (photobiomodulation) can help slow or improve vision loss from reticular pseudodrusen, a specific type of retinal damage seen in age-related macular degeneration. The laser delivers safe light energy to stimulate healing in the eye.
This trial tests if transplanting lab-grown retinal cells (RPE cells) into the eye can help people with late-stage dry AMD. It aims to slow vision loss and possibly improve sight.
This trial tests whether a special light treatment (photobiomodulation) can help people with dry age-related macular degeneration (AMD). It is designed for those with early to moderate dry AMD who still have fairly good vision.
This study tests a light-based treatment (photobiomodulation) for dry AMD, using the Valeda Light Delivery System. It may help improve vision and eye health over time.
This trial tests a new light-based treatment for intermediate age-related macular degeneration (AMD), a common eye condition that can lead to vision loss. The goal is to see if it is safe and helps slow down the disease.
This trial tests a new type of electrical stimulation, called microcurrent therapy, to see if it can help people with a certain form of age-related macular degeneration (AMD) that is not the "wet" kind. The treatment is delivered through an eye patch-like device and may slow vision loss or improve function.
Hear when a new AMD - Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.